Today: 15 October 2025
Subscribe
BigBear.ai (BBAI) Stock Rockets 80% in 2025 – Is the Defense-AI Rally Just Beginning?
 ·  ·  ·  · 

BigBear.ai (BBAI) Stock Rockets 80% in 2025 – Is the Defense-AI Rally Just Beginning?

by
13 October 2025
  • Price: ~$7.24 (closing Oct 10, 2025) [1] (after-hours ~7.71). BigBear.ai’s stock is up roughly 78–82% year-to-date (2025) [2], and about +422% over one year [3].
  • Recent News: BigBear.ai partnered with SMX for the U.S. Navy’s UNITAS 2025 exercise [4] and deployed its “veriScan” biometric screening at Nashville Airport [5]. These deals bolster its government/security profile.
  • Financials: Q2 2025 revenue was $32.5M (–18% YoY) [6]; GAAP net loss was $228.6M (vs –$14.4M a year ago) [7], due to large one‑time charges. Management cut 2025 sales guidance to ~$125–$140M [8]. As of Q2 it held ~$390M cash and a ~$380M contract backlog [9] [10].
  • Analysts: Wall Street is mixed/neutral. Consensus is “Hold” (2 Buys, 2 Holds, 1 Sell) with a 12‑month target around $6.00 [11] (≈–17% from today). Bullish analysts (Cantor, H.C. Wainwright) have Buy ratings with higher targets ($6–$8) citing BigBear’s backlog and rising defense/AI budgets [12] [13].
  • Industry: BigBear.ai is often called a “mini-Palantir” for defense analytics [14]. For comparison, Palantir (PLTR) trades near $175 (up ~300% YTD) [15], with ~$1.03B revenue in Q2 [16] (vs BBAI’s $32.5M). Fellow AI firm C3.ai (AI) also competes for government contracts, but has lagged in growth. U.S. government AI/defense funding is surging (a new ~$300B budget dubbed the “One Big Beautiful Bill” [17]).
  • Risks/Sentiment: The stock is highly volatile (implied vol ~136%, RSI overbought) [18]. Despite recent highs, BBAI remains ~69% below its 2021–22 peak [19]. Retail sentiment is extremely bullish (trending on StockTwits after Navy news) [20], but quantitative models score it poorly: e.g. Validea’s Small-Cap Growth screen rates BBAI only 45% (profit and growth metrics “Fail”) [21]. Investors should weigh the hype against the company’s weak margins and loss history.

BigBear.ai is a publicly traded AI firm (NYSE: BBAI) based in McLean, Virginia, specializing in “mission-ready AI” solutions for the U.S. government and critical infrastructure [22]. Founded via a 2021 SPAC merger, it leverages machine learning, sensor fusion and advanced analytics to support defense, intelligence, homeland security and customs operations. Its products (e.g. the Arcas™ computer-vision system and ConductorOS edge-AI platform) deliver real-time insights to military and border-security customers. In short, BigBear.ai positions itself as a niche AI analytics vendor – a smaller counterpart to firms like Palantir [23] – with deep ties to defense agencies.

Current Stock Price & Performance

BigBear.ai stock has surged sharply in 2025. After trading below $2 in late 2024, BBAI closed at $7.24 on Oct. 10, 2025 [24]. It had closed about $7.49 on Oct. 9, reflecting a 78–82% YTD gain [25]. (For context, Palantir shares rallied ~300% in 2025 [26].) The rally came in leaps and bounds: for example, news of the Navy UNITAS exercise on Sept 23 lifted BBAI ~11–13% in a day [27]. Conversely, its Q2 earnings miss in August caused a 20–25% one-day drop [28]. Trading has been extremely volatile – intraday swings of 10–14% were common in September [29], and trading volumes spiked on news events. By late Sep the stock’s RSI hit overbought territory [30], and implied volatility is roughly 136% [31], suggesting a likely pullback in the near term if no new catalysts emerge.

Recent News & Strategic Developments

BigBear.ai has announced several high-profile collaborations and contracts in the past few weeks. On Sept 23, 2025 it revealed a partnership with SMX for the U.S. Navy’s UNITAS 2025 exercise [32]. In this multinational maritime drill (Sept 15–Oct 6), BBAI will deploy its AI-powered sensor-fusion and domain-awareness tools on unmanned vehicles to track illicit trafficking and improve fleet situational awareness [33]. CEO Kevin McAleenan noted this “underscores BigBear.ai’s commitment to equipping U.S. and allied forces with mission-ready AI” [34]. Earlier (Sept 11), BigBear.ai began supporting U.S. Customs at Nashville International Airport with its “veriScan” biometric passenger-processing system [35]. The company says this facial-recognition solution lets eligible travelers bypass passport checks, speeding Customs clearance [36].

These recent wins add to a growing pipeline of government work. Notably, BigBear.ai landed a five-year $165.15M U.S. Army contract in late 2024 for the Army’s Global Force Information Management program [37]. The company also cites previous projects in Middle Eastern customs and Panama cargo security. (It even bought naming rights to the NFL’s Washington Commanders’ facility – largely a branding play.) Meanwhile, management trimmed 2025 guidance: it now expects roughly $125–$140M in 2025 revenue (vs $160–$180M before) [38] and has withdrawn profit targets amid execution uncertainty. The consensus view is that BigBear’s recent defense/AI deals (Navy, biometrics, etc.) have offset investor concerns from the Q2 miss [39], bolstering confidence in its long-term positioning.

Financials & Outlook

BigBear.ai’s fundamentals remain challenging. In Q2 2025 the company reported $32.5M in revenue (down 18% YoY) [40], well below expectations. Profitability was worse: GAAP net loss hit –$228.6M [41] (versus –$14.4M a year ago), driven largely by non-cash items (≈$135.8M from a convertible-note revaluation and a $70.6M goodwill write-down) [42]. On an adjusted basis (excl. one-offs), the underlying business still burned cash (Adj. EBITDA roughly –$8.5M) due to low gross margins (~25%) and elevated R&D spend [43]. Thus far there is no clear path to profitability: BigBear’s annual revenues have grown only in the single digits (≈3% CAGR) while expenses are high [44] [45].

That said, the balance sheet is strong. Q2 cash was about $390.8M [46], up sharply from last year. Long-term debt is “modest” and the contract backlog stands at ~$380M [47] – offering some future revenue visibility. These buffers underpin some analysts’ optimism, but the valuation is rich relative to sales (TS2 notes ~13× 2025 revenues) [48]. Looking ahead, the 6–12 month forecast hinges on execution: optimists argue that landing more government contracts (and leveraging the large cash reserves) could push BBAI to the upper end of analyst targets (~$6–$8) [49] [50]. Pessimists counter that without better margins or a scalable product line, the stock could revisit lower levels. Overall, Medium-term expectations are cautious: Wall Street’s average 1-year target is around $6.00 [51] (implying ~20% downside).

Analyst Commentary & Price Targets

Wall Street’s view is split. Cantor Fitzgerald’s Jonathan Ruykhaver (Buy) raised his target to $6 on Sept 2025, citing BigBear’s ~$380M backlog and strategic acquisitions [52]. Similarly, H.C. Wainwright’s Scott Buck (Buy) set a $8 target, noting that BigBear’s Q2 miss was largely timing-related and that the company “could benefit from the new $300B+ ‘One Big Beautiful Bill’ defense/AI budget” [53]. These bulls believe continued defense spending will drive growth. By contrast, MarketBeat reports the consensus (“Hold” from 2 buys, 2 holds, 1 sell) with a $6.00 average target [54]. The high/low targets among analysts are $8.00 and $4.00 [55] (data aggregator AlphaSpread shows a mean 1-year target of only $4.85 [56]). In short, analysts generally assume BBAI will trade in the $5–8 range next year, unless the company beats expectations. Many technical and quantitative indicators, however, suggest caution: TS2’s technical analysis points out that BBAI’s RSI and momentum are already overheated [57].

Industry Trends & Competitors

BigBear.ai operates in a hot defense-AI niche. U.S. defense and intelligence agencies are pouring money into AI and analytics [58]. To illustrate the scale, larger players have exploded: Palantir (PLTR) – BigBear’s closest big-cap peer – trades near $175 (Oct 13, 2025) after rallying ~300% YTD [59]. By contrast, BigBear.ai’s latest quarter was only $32.5M in sales [60]. Palantir’s Q2 revenue (~$1.03B) dwarfed BigBear’s [61]. Fellow analytics firm C3.ai (AI) also serves government customers, but its revenue growth has been more modest and its 2025 stock performance flat. In general, BigBear.ai sells highly customized solutions, so its gross margins (~25–30%) are far below Palantir’s (~80%) [62]. If BigBear is to keep pace, it must scale up rapidly. Its advantage is deep government ties; its risk is that more agile or well-funded competitors (including large defense contractors adding AI) may capture market share.

Risks & Investor Sentiment

Investing in BBAI carries clear risks. Despite recent gains, BBAI remains far below past highs – it traded above $16 in April 2022 and is still ~69% below that peak [63]. The stock has been a rollercoaster: after surging in September, it can drop sharply on bad news (e.g. the Aug earnings miss) [64]. Implied volatility is extremely high (~136%) [65], and technical indicators suggest the rally is over-extended. Retail investors have been very enthusiastic (stock tickers and social media have buzzed about this “AI-defense play” [66]), but fundamental metrics lag. BigBear.ai’s losses are still mounting (it burned through cash in Q2 [67]), and it has a history of equity dilution. Quantitative models reflect these weaknesses: for instance, Validea’s Motley Fool Small-Cap Growth model scores BBAI just 45% (with FAIL grades on profit margin, sales and EPS growth, and cash flow) [68]. In a nutshell, the risk factors include BigBear.ai’s low margins, continued red ink, and dependence on federal funding. Until its revenues stabilize and costs shrink, many analysts believe the stock could retrace if investor enthusiasm fades [69] [70].

In summary, BigBear.ai has become an “AI defense darling” in the market, powered by new Navy and airport contracts [71] [72] and a supportive budget environment. However, its medium-term outlook (6–12 months) is guarded: analysts expect BBAI to consolidate in a roughly $5–7 range unless it delivers stronger growth. Over the longer term (1–3 years), success hinges on scaling the business. If BigBear.ai can translate its backlog and cash reserves into ongoing revenue growth, it could justify a higher valuation. If not, skeptics warn the stock’s run may fizzle. Investors should watch upcoming contract wins and quarterly results closely before betting on continued upside.

Sources: Authoritative press releases and market reports as cited above [73] [74] [75] [76] [77] [78] [79] [80] [81]. (Graphics from BigBear.ai and competitor announcements.)

Can Big Bear AI Become The Next Palantir?! 🤔
Watch this video on YouTube.

References

1. www.marketbeat.com, 2. ts2.tech, 3. ts2.tech, 4. ir.bigbear.ai, 5. ts2.tech, 6. ts2.tech, 7. ts2.tech, 8. ts2.tech, 9. ts2.tech, 10. ts2.tech, 11. ts2.tech, 12. ts2.tech, 13. ts2.tech, 14. ts2.tech, 15. ts2.tech, 16. ts2.tech, 17. ts2.tech, 18. ts2.tech, 19. ts2.tech, 20. ts2.tech, 21. ts2.tech, 22. ts2.tech, 23. ts2.tech, 24. www.marketbeat.com, 25. ts2.tech, 26. ts2.tech, 27. ts2.tech, 28. ts2.tech, 29. ts2.tech, 30. ts2.tech, 31. ts2.tech, 32. ir.bigbear.ai, 33. ir.bigbear.ai, 34. ir.bigbear.ai, 35. ts2.tech, 36. ts2.tech, 37. www.businesswire.com, 38. ts2.tech, 39. ts2.tech, 40. ts2.tech, 41. ts2.tech, 42. ts2.tech, 43. ts2.tech, 44. ts2.tech, 45. ts2.tech, 46. ts2.tech, 47. ts2.tech, 48. ts2.tech, 49. ts2.tech, 50. ts2.tech, 51. ts2.tech, 52. ts2.tech, 53. ts2.tech, 54. ts2.tech, 55. ts2.tech, 56. ts2.tech, 57. ts2.tech, 58. ts2.tech, 59. ts2.tech, 60. ts2.tech, 61. ts2.tech, 62. ts2.tech, 63. ts2.tech, 64. ts2.tech, 65. ts2.tech, 66. ts2.tech, 67. ts2.tech, 68. ts2.tech, 69. ts2.tech, 70. ts2.tech, 71. ts2.tech, 72. ts2.tech, 73. ir.bigbear.ai, 74. ir.bigbear.ai, 75. www.businesswire.com, 76. ts2.tech, 77. ts2.tech, 78. ts2.tech, 79. ts2.tech, 80. www.marketbeat.com, 81. ts2.tech

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. Redwire (RDW) Shares Plummet on Shake-Up – Is a Takeoff Next?
  2. HOVR Stock Rockets as Horizon Aircraft Lands Pratt & Whitney Engine Partnership
  3. Rocket Lab (RKLB) Stock Blasts Off: Japan Launch Deals and Analyst Upgrades Fuel 700% Rally
  4. Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Related Articles

Nor’easter on Steroids: Coastal Chaos as Storm Knocks Out Power, Flooding Threatens Millions
Previous Story

Nor’easter on Steroids: Coastal Chaos as Storm Knocks Out Power, Flooding Threatens Millions

Powell Max (PMAX) Stock: Hidden Gem or Sinking Ship? Experts Weigh In
Next Story

Powell Max (PMAX) Stock: Hidden Gem or Sinking Ship? Experts Weigh In

Stock Market Today

  • BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%
    October 15, 2025, 3:16 PM EDT. BRISTOL-MYERS SQUIBB CO (BMY) is identified as a large-cap growth stock in the Biotechnology & Drugs sector. Under Validea's guru-based evaluation, BMY ranks highest on the P/B Growth Investor model crafted from Partha Mohanram's framework. The stock earns an 88% score, signaling substantial interest (scores ≥80% indicate some interest; >90% signal strong interest). In the table of tests, key metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS show PASS; several items remain favorable, such as R&D TO ASSETS and CAPEX TO ASSETS. The analysis highlights the model's emphasis on low book-to-market with growth traits, and provides context on Mohanram's contribution to factor-based investing.
  • BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strength
    October 15, 2025, 3:14 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model, scoring 88% based on Partha Mohanram's growth framework. The model seeks low book-to-market stocks with indicators of sustained future growth. BMY is categorized as a large-cap Biotechnology & Drugs name, and the 88% reading suggests substantial interest (80% threshold signals interest; 90% signals strong interest). The summary table shows most tests pass, including Book/Market Ratio, Return on Assets, CFO/Assets, CFO/Assets vs ROA, Operating Cash Flow to Assets, and Advertising to Assets. Notably, R&D to Assets is flagged as failed. Overall, this factor-based view highlights BMY as a potential growth candidate within pharma, though investors should weigh the R&D asset treatment and broader biotech cycle.
  • BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model
    October 15, 2025, 3:12 PM EDT. Bristol-Myers Squibb Co (BMY) lands the highest score in Validea's Partha Mohanram P/B Growth Investor model, a framework that seeks low book-to-market stocks with sustained growth. As a large-cap biotechnology stock, BMY earns an 88% rating based on fundamentals and valuation, signaling notable investor interest (80%+) and potential strong interest (>90%). The table shows mixed results: PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO to assets vs ROA, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and R&D TO ASSETS (PASS); however R&D TO ASSETS is listed as FAILED. The analysis reflects Mohanram's approach to distinguish growth winners from losers, with BMY aligned to growth criteria despite R&D-related weak point.
  • BMY Tops Partha Mohanram P/B Growth Signals in Validea Guru Report
    October 15, 2025, 3:10 PM EDT. Bristol-Myers Squibb Co (BMY) shows the strongest signal among Validea's 22 guru strategies under Partha Mohanram's P/B Growth Investor model. The growth framework targets low book-to-market stocks with growth traits. BMY scores 88% under this strategy, with thresholds of 80% indicating interest and above 90% signaling strong interest. The stock is classified as a large-cap growth name in Biotechnology & Drugs. The criteria largely pass (Book/Market, ROA, CFO ratios, operating metrics), with one exception: Research and Development to assets FAILED. Overall, the report presents BMY as a compelling growth candidate within the guru framework, though not a slam-dunk.
  • BMY Factor-Based Stock Analysis: Mohanram Growth Model Finds 88% Rating
    October 15, 2025, 3:08 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's guru-based framework, led by Partha Mohanram's P/B Growth Investor model. The low book-to-market, sustained-growth criteria yield an 88% rating, with a typical threshold of 80% for interest and 90% for strong interest. The report shows the stock passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics like R&D TO ASSETS and CAPEX TO ASSETS. While not all criteria are equal, the overview highlights BMY as a large-cap growth play in Biotechnology & Drugs with favorable fundamentals and valuation signals per Mohanram's framework. Overall, the analysis suggests notable interest from this factor-based lens, consistent with BMY's growth-oriented profile.
Go toTop